申请人:ONO PHARMACEUTICAL CO., LTD.
公开号:EP2508204A2
公开(公告)日:2012-10-10
A therapeutic and/or preventing agent for a disease due to vascular constriction or vasodilation comprising a EDG-5 modulator. Since EDG-5 modulator specifically binds EDG-5 and shows antagonistic or agonistic action, EDG-5 antagonist is useful for treating and/or preventing for a disease due to vascular constriction, for example, cerebrovascular spasmodic disorder after subarachnoid hemorrhage or stroke, cardiovasucular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure involved in liver cirrhosis, varicosity involved in liver cirrhosis and the like, or EDG-5 agonist is useful for treating and/or preventing for a disease due to vasodilation of blood vessels, for example, chronic headache (such as migraine, tension-type headache, mixed-type headache thereof, or migrainous neuralgia), haemorrhoid, congestive disorder and the like.
一种治疗和/或预防因血管收缩或血管扩张引起的疾病的药物,包括 EDG-5 调节剂。由于 EDG-5 调节剂特异性结合 EDG-5,并显示出拮抗或激动作用,EDG-5 拮抗剂可用于治疗和/或预防血管收缩引起的疾病,例如蛛网膜下腔出血或中风后的脑血管痉挛性疾病、心血管痉挛性疾病、高血压、肾病、心肌梗塞、心绞痛、心律失常、EDG-5激动剂可用于治疗和/或预防因血管扩张引起的疾病,例如慢性头痛(如偏头痛、紧张型头痛、混合型头痛或偏头痛性神经痛)、痔疮、充血性疾病等。